COPD Foundation, DevPro Biopharma Partner to Boost New Therapy Development

Patricia Inacio PhD avatar

by Patricia Inacio PhD |

Share this article:

Share article via email
TrialSpark, Sanofi deal

The Chronic Obstructive Pulmonary Disease Foundation and DevPro Biopharma have established a partnership to develop new therapies for people with chronic obstructive pulmonary disease (COPD) and other lung disorders.

The collaborators will work to identify potential therapies and speed their development and possible regulatory approval. The aim is to enable new treatments to become available to patients sooner.

“By joining forces, DevPro Biopharma will direct its expertise to the development of clinical programs to be conducted within the COPD Foundation’s network,” Colin Reisner, MD, co-founder and CEO of DevPro Biopharma, said in a press release.

“We are confident that through this alliance we will have a meaningful impact on patient communities worldwide,” Reisner added.

DevPro Biopharma’s extensive expertise in the design and implementation of clinical trials will be allied with the COPD Foundation’s network of experts, called COPD360Net.

Launched in 2020, the COPD360Net’s mission is to foster the development and approval of new digital health tools and treatments for people with COPD and related chronic lung diseases, with the aim of preventing disease progression and improving patient’s lives.

It is a network of core foundation-accredited care centers, experts in COPD and related lung diseases, and leaders in primary care, health economy, and psychology. The project was designed with a patient-centered approach to accelerate clinical research and expand the therapeutic options for COPD.

“The COPD Foundation is home to many of the world’s leading experts in chronic lung conditions. Now, through their new COPD360Net initiative, they are poised to become leaders in the development of new therapeutics,” Reisner said.

DevPro Biopharma has been involved in the approval of several respiratory products, including inhaled medicines. Its team of experts cover all aspects of clinical development, from study design to product submission and approval, with the aim of accelerating clinical development, reducing the approval timelines of potential therapies, and optimizing their cost.

“Patients are desperate for additional treatment options, especially those that will prevent disease progression,” said Ruth Tal-Singer, PhD, president and chief scientific officer of the COPD Foundation.

“This strategic alliance with DevPro Biopharma helps us build upon our improved understanding of the needs of patients across the spectrum of COPD and related lung conditions. With this partnership, we aim to deliver on our mission of ensuring the rapid approval of innovative, impactful and affordable treatment options for our community,” she added.